UroGen Pharma Ltd. - Ordinary Shares (URGN) News

UroGen Pharma Ltd. - Ordinary Shares (URGN): $13.73

0.53 (-3.72%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add URGN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#47 of 362

in industry

Filter URGN News Items

URGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

URGN News Highlights

  • URGN's 30 day story count now stands at 2.
  • Over the past 11 days, the trend for URGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest URGN News From Around the Web

Below are the latest news stories about UROGEN PHARMA LTD that investors may wish to consider to help them evaluate URGN as an investment opportunity.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., December 08, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 17 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the

Yahoo | December 8, 2023

Shareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years ago

UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders should be happy to see the share price up 17% in the last month. But...

Yahoo | November 27, 2023

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker […]

Yahoo | November 15, 2023

UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials

Net Revenue Rises as Company Advances with UGN-102 Clinical Development

Yahoo | November 14, 2023

UroGen Pharma Reports Third Quarter 2023 Financial Results

PRINCETON, N.J., November 14, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent developments.

Yahoo | November 14, 2023

UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology

PRINCETON, N.J., November 13, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, will highlight data from two key Phase 3 trials evaluating UGN-102, an investigational treatment in development for LG-IR-NMIBC at the 2023 Society of Urologic Oncology (SUO) annual meeting, November 28-December 1 in Washington D.C. These data presentations further UroGen’s mission of developing and comme

Yahoo | November 13, 2023

UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

PRINCETON, N.J., November 07, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2023 financial results on November 14, 2023, at 8:00 AM EDT, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

Yahoo | November 7, 2023

Institutional investors own a significant stake of 50% in UroGen Pharma Ltd. (NASDAQ:URGN)

Key Insights Institutions' substantial holdings in UroGen Pharma implies that they have significant influence over the...

Yahoo | October 30, 2023

Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024

PRINCETON, N.J., October 03, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on plans for submission of a New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution. The FDA indicated that the current clinical development plan for UGN-102, which includes evaluation of du

Yahoo | October 3, 2023

UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J., August 31, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in September:

Yahoo | August 31, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!